Cancer drug developer, Antisoma, says that it is planning to list its shares on the technology-heavy US stock index, Nasdaq.

As an interim step, the firm says it will establish a Level I programme of American Depositary Receipts to enable dollar-denominated trading of its ordinary shares prior to the listing.

Antisoma’s chief executive, Glyn Edwards, said: “We already have a significant number of US shareholders. Listing in the US will increase our exposure to the US capital markets, a step that we believe will greatly enhance our long-term growth prospects and our ability to exploit new opportunities for development.”